PepGel™ PGmatrix™
Injection Platform

Defined, Biocompatible Hydrogel for in vivo Delivery

PepGel™ PGmatrix™ Injection is a next-generation, peptide-based solubilized basement-membrane substitute designed to mimic the human ECM that supports cytocompatibility, cell maintenance, and growth in vivo. Synthesized entirely from commonly used amino acids and essential minerals found in the human body, PGmatrix Injection provides a reproducible, well-defined and animal-free solution for reliable cell transplantation and preclinical modeling [1,2,3]. It also supports sustained release and delivery of viruses, biologics, and growth factors in vivo, such as bone morphogenetic protein (BMP) based molecules [4].

Composition & Compatibility

Amino acid–rich formulation: Includes Arginine, Aspartate, Glycine, Isoleucine, Leucine, Lysine, Phenylalanine, Proline, Serine, Valine, Glutamate, and water.

Two-component system:

• Solution A – PGwoks-iv solution (optional, it is non-chemical, non- enzyme, xeno-free solution).
• Solution B – PGmatrix™ our well-defined xeno-free synthetic peptide nanofiber solution.

• No icing required: All operations and steps prior to in vivo delivery can be performed at room temperature or 37 °C under neutral pH, eliminating acidic or cold-stress conditions.
• Simple, targeted delivery: cells or other cargos are easily encapsulated and injected to the desired in-vivo site; PGmatrix™ degrades into amino acids and is readily absorbed, allowing encapsulated cells to be released and function as intended.
• Well-defined & reproducible: Composed of fully characterized xeno-free components to ensure consistency across experiments and applications.
• Highly biocompatible: Demonstrated biocompatibility with biological environments and low risk of infection while accurately reflecting the native cell microenvironment.
• GMP – Certified PGmatrix™ Injection:  DMF (Drug Master Filing) to be submitted to the FDA (Food and Drug Administration) is in process and will be available soon.

• Preclinical therapeutic cell delivery (e.g., organ cells, stem cells, T-cells, cancer cells).
• Sustained release of viruses, biologics, or growth factors for in vivo studies requiring a physiologically relevant ECM scaffold.
• Xenograft and tumor-formation in animal models.

• PG1007-010-IJ, The best option for in vivo delivery of cells, virus, antigens, exosomes, other biologics, as well as targeted proteins and peptides.  It serves as an “adjuvant” for biological drugs to improve drug efficacy.